Clinical Trials
Enrolling Trials
111-120 of 125
s2010-A Randomized Phase III Trial Comparing Active
Symptom Monitoring Plus Patient Education Versus Patient
Education Alone to Improve Persistence With Endocrine
Therapy in Young Women With Stage I-III Breast Cancer
(ASPEN)
Onitilo, Adedayo A
Breast - Breast
Adult
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Wilson, Anna E
(715) 858-6860
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Neillsville
216 Sunset Place
Neillsville, Wi 54456
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S2012-Randomized Phase II/III Trial of First Line
Platinum/Etoposide With or Without Atezolizumab
(NSC#783608) in Patients With Poorly Differentiated
Extrapulmonary Small Cell Neuroendocrine Carcinomas
(NEC)
Delmastro, Dean A
Oncology - Lung
Adult
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) small cell neuroendocrine cancer. The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary small cell neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.
Wilson, Anna E
(715) 858-6860
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S2013 - Immune Checkpoint Inhibitor Toxicity (I-CHECKIT):
A Prospective Observational Study
Jahn, Shannon
Cancer Supportive Care - Other
Adult
This study examines the side effects that occur from receiving immunotherapy (immune checkpoint inhibitor) in patients with malignant solid tumors. Immunotherapy is the type of treatment that helps your immune system fight cancer. In the future, this information may help participants and their doctors make better decisions about cancer treatments.
Wilson, Anna E
(715) 858-6860
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S2015-Melanoma Margins Trial-II - A Phase III, Multi-centre
Randomised Controlled Trial Investigating 1cm v 2cm Wide
Surgical Excision Margins for AJCC Stage II Primary
Cutaneous Melanoma (02.18 MelMarT-II)
Sharma, Rohit
Melanoma - Other
Adult
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Kidwell, Anna
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
S2104-Randomized Phase II Trial of Postoperative
Adjuvant Capecitabine and Temozolomide Versus
Observation in High-Risk Pancreatic Neuroendocrine
Tumors
Fagbemi, Seth O
Stomach, Intestine, Gut - Pancreas
Adult
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Kidwell, Anna
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S2107-Randomized Phase II Trial of Encorafenib and
Cetuximab With or Without Nivolumab (NSC #748726) for
Patients With Previously Treated, Microsatellite Stable,
BRAFV600E Metastatic and/or Unresectable Colorectal
Cancer
Onitilo, Adedayo A
Stomach, Intestine, Gut - Rectum
Adult
This phase II trial tests whether encorafenib and cetuximab with and without nivolumab works to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Encorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for proliferation. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.. Giving encorafenib and cetuximab with nivolumab may be more effective at stopping the growth of new cancer cells in patients with metastatic or unresectable colorectal cancer than encorafenib and cetuximab alone.
Humphrey, Logan J
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S2200-A Phase II Randomized Trial of Cabozantinib (NSC
#761968) With or Without Atezolizumab (NSC #783608) in
Patients With Advanced Papillary Renal Cell Carcinoma
(PAPMET2)
Fagbemi, Seth O
Kidney Tumors
Adult
This phase II trial tests whether cabozantinib with or without atezolizumab works to shrink tumors in patients with papillary kidney cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with atezolizumab may prevent papillary kidney cancer from growing or spreading compared to cabozantinib alone.
Kidwell, Anna
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S2207-Randomized Phase II Study of the Addition of
Targeted Therapeutic Agents to Tafasitamab-Based
Therapy in Non-Transplant-Eligible Patients With
Relapsed/Refractory Large B-Cell Lymphoma
Delmastro, Dean A
Lymph Gland
Adult
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.
Wilson, Anna E
(715) 858-6860
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
S2212-Shorter Anthracycline-Free Chemo Immunotherapy
Adapted to Pathological Response in Early Triple Negative
Breast Cancer (SCARLET), A Randomized Phase III Study
Gokalp Yasar, Demet
Breast - Breast: Adjuvant - Triple Negative
Adult
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Humphrey, Logan J
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Gokalp Yasar, Demet
Breast - Breast
Adult
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Craig, Chani L
(715) 358-1838
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2116 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
,
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476